Alpha Seven

Alpha-7 Therapeutics is a clinical-stage biotechnology company focused on the development of targeted alpha-particle therapies (TATs) for the treatment of solid tumors. The company's lead candidate, A7-101, is an Actinium-225 labeled small molecule targeting prostate-specific membrane antigen (PSMA), currently being evaluated in a Phase 1 clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC). Alpha-7's proprietary platform optimizes the delivery of potent alpha radiation to cancer cells while minimizing damage to healthy tissue by utilizing high-affinity ligands and advanced radiochemistry. Founded by radiopharmaceutical pioneer Dr. David J. Yang, the company aims to expand its pipeline to address various high-unmet-need oncology indications. Alpha-7 is part of a specialized group of companies advancing the therapeutic potential of alpha-emitting isotopes in precision oncology.